The Glide technology can be used for a broad range of applications including:
Biologic drugs
The Glide SDI offers a means for peptide and protein based therapeutics that cannot be taken orally, to inject stable, solid formulations. Potential drug candidates include insulin and erythropoietin.
Proprietary & generic drugs
The Glide SDI provides the opportunity to deliver stable solid formulations through the skin, improving drug delivery; offering product differentiation and patent extension options. Potential drug candidates include interferon alpha and interferon beta.
Self administered drugs
The use of the Glide SDI for self administration provides a quick, easy, clean and safe way to use at home with minimal training; no sharps disposal required and stable solid formulation which may not require refrigeration. Potential drug candidates include the human growth hormone and migraine treatments.
Vaccines
The Glide technology eliminates the need for a separate reconstitution media; potential for improved stability; low cost manufacturing; fast and simple application; non-clinical data (with influenza) suggests enhanced immune response for antigens delivered with the Glide SDI. Potential drug candidates include hepatitis B, measles, tuberculosis and influenza.
Emergency medicines
The Glide SDI offers the potential for mass vaccination with quick and simple administration, carried out with minimal training; easy to store and carry, with long-term stability. Potential drug candidates include adrenalin and glucagon.
Biodefence
The Glide SDI provides quick and simple administration with minimal training; low cost manufacture on a large scale; stable formulations can be stockpiled. Potential drug candidates include anthrax, smallpox and influenza vaccines.
